Results 71 to 80 of about 50,591 (247)

Incidence of Clinical and Subclinical Cystoid Macular Edema in Diabetic and Non-Diabetic Patients After Cataract Surgery by Means of Optical Coherence Tomography

open access: yesDelhi Journal of Ophthalmology, 2018
Purpose: To evaluate the incidence of clinical and subclinical cystoid macular edema in diabetic and non-diabetic patients after cataract surgery by means of Optical Coherence Tomography (OCT).
Aditi Chinmay Deshpande   +2 more
doaj   +1 more source

Functional deficits precede structural lesions in mice with high-fat diet-induced diabetic retinopathy [PDF]

open access: yes, 2016
Obesity predisposes to human type 2 diabetes, the most common cause of diabetic retinopathy. To determine if high-fat diet–induced diabetes in mice can model retinal disease, we weaned mice to chow or a high-fat diet and tested the hypothesis that diet ...
Bligard, Gregory W   +5 more
core   +2 more sources

Neovascular age‐related macular degeneration without drusen

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To describe the clinical characteristics and 1‐year follow‐up of patients with neovascular AMD (nAMD) without drusen in either eye. Methods This is a multicentre retrospective cohort study in three tertiary referral centres in The Netherlands. We included patients of 55 years or older with nAMD in one or both eyes, without the presence
Marc J. Sirks   +9 more
wiley   +1 more source

Blood Flow Parameters of the Central Retinal and Internal Carotid Arteries in Asymmetric Diabetic Retinopathy

open access: yesJournal of Ophthalmic & Vision Research, 2012
Purpose: To investigate the correlation between diabetic retinopathy severity and blood flow parameters in the central retinal artery (CRA) and internal carotid artery (ICA).
Morteza Mehdizadeh   +4 more
doaj  

Visual acuity and macular thickness in diabetic retinopathy treated with panphotocoagulation [PDF]

open access: yes, 2008
OBJETIVO: Comparar espessura macular e acuidade visual em pacientes portadores de retinopatia diabética, com e sem edema de mácula, submetidos à panfotocoagulação retiniana com laser de argônio.
MAIA JÚNIOR, Otacílio de Oliveira   +2 more
core   +2 more sources

Diabetic retinopathy in Greenland and Denmark—Can differences in risk factors explain the lower prevalence in Greenland?

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose The prevalence of diabetic retinopathy (DR) is low in Greenland. Factors underlying the low prevalence may potentially protect against the development of DR. Comparing Greenlandic and Danish populations, this register‐based study explored differences in risk factors that may explain differences in DR prevalence.
Jonas Bjørn Skjøth   +4 more
wiley   +1 more source

Health Economic Considerations for the Implementation of Artificial Intelligence‐Enabled Diabetic Retinopathy Screening: A Review

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Artificial intelligence (AI) has comparable accuracy to ophthalmologists for diabetic retinopathy (DR) screening, yet its cost‐effectiveness is crucial for implementation. Our review of 18 health economic analyses of AI versus manual grading for DR found significant methodological variation, with cost‐utility analysis and Markov modelling ...
James Leigh   +3 more
wiley   +1 more source

Treatment chronic macular edema in Vogt-Koyanagi Harada syndrome with dexamethasone intravitreal implant: description of three case [PDF]

open access: yes, 2015
Purpose: To report our experience with dexamethasone intravitreal implant (Ozurdex, DEX implant) in the chronic cystic macular edema (ME )with Vogt-Koyanagi-Harada (VKH) Syndrome. Method: A retrospective chart review of three patients with (VKH) treated
Albanese, Giorgio   +5 more
core   +1 more source

Once‐weekly insulin icodec versus once‐daily insulin degludec for type 2 diabetes in China: A cost‐utility and budget impact analysis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Insulin icodec, the first once‐weekly basal insulin analogue, was approved in China in 2024. Although it has demonstrated robust clinical efficacy, its budget impact remains unknown, and the long‐term cost‐utility within the reimbursement context needs further estimates.
Xichen Tong   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy